Safety and Clinical Outcomes of an Equine-derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States
Clicks: 87
ID: 261557
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
25.8
/100
87 views
13 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #826 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The effectiveness of Botulinum Antitoxin Treatment drug product is based on efficacy studies conducted in animal models. An observational patient registry was c
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (23 words).
Try re-searching for a better abstract.
| Reference Key |
s2020clinicalsafety
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Richardson, Jason S;Parrera, Geraldine S;Astacio, Hugo;Sahota, Harpreet;Anderson, Deborah M;Hall, Christine;Babinchak, Tim; |
| Journal | clinical infectious diseases |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.